anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A controlled release bead, suitable for the controlled release of a medicament on internal administration, comprises (a) a core comprising a uniform mixture of a medicament and a water-swellable colloid and (b) a film coating surrounding and contacting the core, the coating being inert to body fluid, permeable to the diffusion of water, and capable in use of being ruptured by the swelling of the colloid-containing core, whereby in use on prolonged exposure to body fluid, sufficient water diffuses through the coating and causes the core to swell to an extent such as to rupture the coating, thereby resulting in the substantially immediate and total release of the medicament into the body fluid.  The colloid may be starch, starch phosphate, zein, gum arabic, agar, albumin, tragacanth, or gelatin-starch mixtures and is preferably gelatin containing less than 11% by weight of water.  The film coating may be formed from a plastics material, e.g. ethyl cellulose, a chlorotrifluoroethylene or tetrafluoroethylene resin or a vinyl chloride/ vinylidene chloride copolymer.  A pharmaceutical composition comprises a plurality of the controlled release beads and a carrier, e.g. a gelatin capsule, the cores preferably each containing the same proportion of medicament. The water permeability of the film coating of each bead used in a composition may be selected from a progressive series over a predetermined range, thereby resulting in use in the serial rupture of the coatings of the beads and the controlled release of the medicament.  The plastics film coating is preferably applied to the dry core by vertical spray drying.
The purpose of this research was to investigate the potential predictive value of preoperative systemic inflammatory indexes in identifying lymph node metastasis among patients diagnosed with small bowel cancer. A retrospective analysis of clinical data was conducted on small bowel cancer patients who underwent surgical treatment at the gastrointestinal surgery department of our hospital between January 2010 and June 2021. Patients were divided into groups based on the presence or absence of lymph node metastasis as confirmed by postoperative pathological results. The study compared the differences in preoperative inflammatory indexes and clinical data between the two groups using single factor analysis and multifactorial Logistic regression analysis. Furthermore, a nomogram model for predicting lymph node metastasis in colorectal cancer was constructed using R software and internally validated. The study sample consisted of 140 small bowel cancer patients,postoperative pathology confirmed lymph node metastasis in 72 cases. Univariate analysis results indicated associations between preoperative inflammatory indexes and clinical data with lymph node metastasis in small bowel cancer. Multifactorial logistic regression analysis revealed that gender, PLR, number of lymph node dissection, and lymphovascular invasion independently influenced lymph node metastasis in small bowel cancer patients. The developed nomogram model demonstrated a C-index of 0.855 (95% CI 0.792-0.917), with a calibrated prediction curve closely resembling the ideal curve. An elevated PLR is an independent risk factor for LNM in patients with small bowel cancer.
20 subjects free of malignancy (Male-Female Ratio 2 to 1) the variation in the concentration of DNA circulating between the value measured on an empty stomach after 1 hour of rest, then at the end of each of the successive stages of moderate intensity physical effort: pedaling 15 minutes at 75 Watt then 100 Watt of the ergometer. Dosages will be repeated after 15, 30 and 60 minutes of recovery. After an hour of recovery, the subject will be asked to consume a meal rich in fat. The circulating DNA will be measured 2 hours after the end of the meal.

40 patients with colon cancer will be enrolled for a two visit study. The first visit will be planned at the first cycle of chemotherapy, before the chemotherapy. At this visit, the influence of exercise on plasma concentrations of circulating free DNA will also be studied in 40 patients with colon cancer. Free circulating DNA will be measured on an empty stomach after 1 hour of rest, then immediately after low-intensity physical effort : pedaling 3 minutes at the 30 Watt level of the ergometer) and after 15, 30 and 60 minutes of recovery. After an hour of recovery, the subject will be proposed to consume a meal rich in fat. The circulating DNA will be measured 2 hours after the end of the meal. The second visit will be planned at the first second of chemotherapy, before the chemotherapy. Free circulating DNA will be measured on an empty stomach after 1 hour of rest, then immediately after low-intensity physical effort : pedaling 3 min at the 30 Watt level of the ergometer, and after 15, 30 and 60 minutes of recovery.
PURPOSE:The titled inhibitor consisting essentially of bupleurum root saponin d as an active constituent. CONSTITUTION:A methylguinidine production inhibitor containing bupleurum root saponin d, contained in Bupleurum falcatum L. and expressed by the formula as an active constituent. The inhibitor is capable of remitting various symptoms of uremia, delaying the time of introducing dialysis and prolonging the time interval of dialysis. The bupleurum root saponin d expressed by the formula is obtained by extracting a root of Bupleurum falcatum L. with an aqueous solvent of an alcohol, e.g. methanol or ethanol, distilling away the solvent from the extract solution, adding ether to the extract, heating the resultant mixture, removing the ether layer, distributing the residue with a water- insoluble organic solvent, e.g. n-butanol or ethyl acetate, and water, subjecting the water-insoluble organic solvent layer to column chromatography, further subjecting the eluate to high-speed liquid chromatography and fractionating the eluate. The dose thereof is 200-200mg/time and orally administered up to 30 times a day.
Intestinal mucormycosis is a rare manifestation of the Mucor fungus, associated with high mortality and typically found in immunocompromised patients, though it has also been described in immunocompetent individuals. The mode of acquisition is digestive. It usually presents as abdominal pain, with ischemia and intestinal perforation, and the diagnosis is often histopathological after surgical resection. We present the case of a 54-year-old female patient with recurrent acute myeloid leukemia undergoing treatment with daunorubicin-cytarabine and experiencing febrile neutropenia. She developed patchy and progressive intestinal ischemia that evolved into intestinal necrosis, which was treated with antifungal medications and surgery. Examination of the surgical specimen revealed aseptate wide hyphae with branching at right angles, suggestive of Mucor fungus. This is a rare but highly mortal pathology in which clinical, radiological, and surgical suspicion is essential for early diagnosis and treatment, thus improving the patient's prognosis.
There have been multiple studies performed to determine a medication that will decrease the pain associated with intrauterine device insertion. These studies have tested the use of misoprostol as well as NSAIDS to determine if these decrease the pain associated with insertion. There has also been one small, poorly performed, study that tested the use of intracervical topical lidocaine prior to IUD insertion. Misoprostol and NSAIDS were found to be non-efficacious in decreasing pain. Topical lidocaine was shown to be effective, however, secondary to this being a poorly performed study, additional studies are needed. This study is to determine if topical lidocaine does indeed decrease the pain associated with insertion of the Mirena® (levonorgestrel intrauterine device).

This is a double blinded experimental study to determine whether or not topical lidocaine gel applied to the cervix and intra-cervically decreases pain associated with insertion of the Mirena® (levonorgestrel intrauterine device). Subjects will be randomized into two groups. One group will receive 2% lidocaine gel on the cervix and intra-cervically. The other group will receive a placebo, which will consist of KY being placed on the cervix and intra-cervically. After the Mirena® (levonorgestrel intrauterine device) is inserted, each subject's pain will be assessed by using a visual analog pain scale, and their response will be recorded on the information form. This pain scale will be assessed at the time of insertion, five minutes after insertion, and ten minutes after insertion. The only other study that researched the use of topical lidocaine prior to insertion of an IUD only recorded a pain scale at the time of insertion. Additional scores will be recorded at five and ten minutes to determine if pain is reduced in those time periods. These time periods have been chosen in order that all of this information can be recorded during a normal office visit. A visual analog pain scale is the scale included which measures pain on a scale of zero to ten with zero being no pain at all and ten being the worst pain of your life. This pain scale will be a scale ranging from zero to ten with faces depicting the amount of pain involved for each score. Since there will be different physicians placing the intrauterine devices, there will be a protocol on how to perform the insertion in an attempt to make all insertions as uniform as possible. A copy of this protocol has been included.
Reciproc Blue group (n=25) : The canals were shaped with in accordance with the manufacturer's recommendations. R25 (25.08) instrument was introduced into the canal with slow pecking movement within a 3 mm range each time. The flutes and remnants were cleaned after 3 pecking moves. Then R40 instrument (40.06) was selected to shape the distal canals as the #20 K file was passively introduced to the working length. The root canals were irrigated with 2 ml of %2,5 sodium hypochlorite after each instrument exchange.
The present invention provides a sterile powder spraying agent used for wound hemostasis and inflammation resistance. The medicine of the present invention is a natural medicine with the functions of hemostasis and inflammation reduction or the effective parts or the monomer of the natural medicine. The present invention is characterized in that each spraying agent is composed of 0.01 to 0.2 g of medicines of wound hemostasis and inflammation reduction, and high-molecular natural assistant materials or synthesized assistant materials which have high biologic affinity and auxiliary function for wound healing, and can be absorbed with the wound healing. Thus, the acceptable medicament in the medicine is produced. The present invention has the integrated effects of bacterium prevention, hemostasis, acesodyne, itchy alleviation, inflammation reduction, blood circulating promotion, stasis elimination, etc., and can rapidly stop the blood of the wound and heal the wound without scars. The resent invention can absorb partial effused liquid of the wound, and can be dispersed and paved to form a protective film to be helpful for the wound healing. The product has convenient use and stable performance, and no stimulating function exists.
PURPOSE:To obtain the subject medical sheet useful as a simple urgent surgical tape for a medical treatment or generally wide use by using a medicine- encapsulating microcapsule in place of a gauze impregnated with a medicine. CONSTITUTION:This medical sheet 5 is obtained by laying a gauze 2 on the upper side of a cover sheet 1, placing a sheet of medicine 3-encapsulating microcapsules 4 thereon and cutting the resultant layered sheet into various shapes corresponding to the size of a diseased part. If the cover sheet 1 is substituted with a self-adhesive sheet 6 some larger than the outer peripheries of the gauze 2 and the sheet of microcapsules 4, the medical sheet can be applied directly to a diseased part. This medical sheet can also be used by setting the sheet on the pad part of a simple urgent surgical tape for generally wide use. Application of the medicine in the microcapsules to a diseased part is carried out by putting the medical sheet so as to cover the diseased part and pressing the cover sheet. Thereby, the wall membranes of the microcapsules are broken and the encapsulated medicine is allowed to flow out.
Procedure to acilar the ester p-acetylamidofenil of the 2-oxybenzoic acid. It consists of the acetilation reaction of p-acetamidofenil-2-oxibenzoato with acetyl chloride in acetonic dissolution, in the presence of an organic base as a capacitor agent of the hydrochloride acid and the reaction temperature. The reaction mixture is concentrated by evaporation to various and the residue is cooled to 0-5 c and filtra. The product obtained is purified following conventional methods. This composite has pharmacological applications as antirreumatic and analgesic agenette. (Machine-translation by Google Translate, not legally binding)
If a patient is randomized to the LB arm, at the appropriate time, under a surgeon's direction, 266 mg of (liposomal bupivacaine) LB in 20 cc of solution was expanded with various amounts of normal saline to cover the appropriate surgical field. Our routine expansion for a bilateral mastectomy is to add 80 mL of saline to 20 mL (266 mg) of LB. In our practice,we use an 18-gauge needle to inject the medication in a "field-effect" encompassing all 4 quadrants of the chest muscles (pectoralis and serratus) followed by injecting around the edges of the skin incision and drain site. This occurs prior to dissection of the pectoralis muscle and implant or tissue expander placement.
A free-flowing binder-disintegrant powder material consisting essentially of a precompacted-starch powder, especially adapted for use in direct compression tabletting machines to produce non-friable tablets having excellent disintegration properties. This precompacted-starch powder is also useful as a free-flowing filler for blending with dry powder ingredients in dry-dosage capsules. The precompacted-starch powder is obtained by subjecting an ungelatinized granular starch to physical compaction without supplementary thermal energy, but with sufficient mechanical energy input to obtain a precompacted-starch having birefringent granules and non-birefringent fragments of granules and some aggregates of granules and fragments, and then dried to a moisture content of 9-16% total weight basis. After precompacting, the starch is pulverized to form a free-flowing powder having a loose bulk density of 0.5 to about 0.7 grams per milliliter. The precompacted-starch powder is essentially free of +40 mesh particles, at least 90% of the particles are -80 mesh, at least about 10% is +270 mesh, and from about 30% to 90% is -270 mesh size on a total weight basis (U.S. Standard Sieve Series, A.S.T.M. Specifications).
Inhaled β2 adrenoceptor agonists are frequently used to treat reversible lower airway obstruction, or to assist with mucociliary clearance. Albuterol remains the most commonly used β agonist and contains a racemic mixture of two enantiomers. The R enantiomer is the active moiety responsible for the bronchodilation, while the S enantiomer was initially thought to be inactive, although recent studies suggest otherwise. Levalbuterol contains the single R form enantiomer, and in clinical practice it is frequently prescribed not only because of its bronchodilator benefits, but to limit cardiovascular toxicity. Adverse cardiovascular effects remain the main dose-limiting factor for β2 agonists. The primary objective of the investigators study is to compare the change in oxygen consumption following albuterol to that of levalbuterol, in healthy adult volunteers. The investigators hypothesized there would be no clinically significant difference in V'O2 between the two drugs, if equal doses of the R-enantiomer were administered. Secondary objectives were to compare the changes in heart rate and other vital signs between the two drugs.
The same anesthesiologist who is experienced in US guided regional anesthesia will perform the block. In the group ESP, a high frequency linear US probe (HFL_50, 15_6MHz) will be placed vertically and nearly 3 cm lateral to the vertebra in the middle of the incision line. The transverse process and the overlaying erector spinae muscles (ESM) will be identified under parasagittal scanning A22 G,50 mm block needle (SONOTAP,Pajunk, Geisingen,Germany) will be inserted at a 30-40° angle in the cranial to caudal direction via an in-plane approach and advanced into the plane between the fascia of ESM and transverse process under sterile conditions. The correct needle position will be confirmed after a hydro dissection with 3 ml of isotonic saline, and then 20 ml of 0.25% bupivacaine will be injected in the interfascial plane between the rhomboideus major muscle and ESM. The local anesthetic spread will be visualized in a fascial longitudinal pattern deep to the ESM.
Systems and methods for analyzing food are disclosed. A first sensor captures first sensor data. A processor determines, based on the first sensor data, whether food has been detected, and invokes a second sensor in response to the determining. The second sensor captures second sensor data. The processor predicts, based on the first and second sensor data, a characteristic of the food. The processor further predicts a body’s response to the food based on the characteristic, and outputs a recommendation based on the predicting of the body’s response.
A disease management system comprises a patient device 12, a healthcare professional device 14 and a database 24 holding parameters relating to diseases and treatment regimes. Data is received from the devices 12, 14 and used to select a treatment regime 28 including at least one medicament and to identify relevant targets 26 to be reached during a treatment timeline 30. When milestones are reached on the timeline the tracking module 32 provides an alert, e.g. an encouraging message or suggesting an alternative regime, relating to the effectiveness of the treatment regime, which may be based on data inputted at the patient device, e.g. measured blood pressure, weight etc, or input by the healthcare professional. The available targets offered may be limited by the system to lie within safe boundaries and indicate medical benefits to the patient. The system facilitates the provision of individualised patient treatment by the provision of feedback mechanisms relating to the efficacy of a current treatment regime. The treatment regime may also comprise a dietary or exercise plan.
Prospective, short-term studies in patients admitted for acute stroke have shown an increased risk of infections, bedsores, impaired functional outcome, slower rate of recovery, poorer rehabilitation potential and higher mortality in patients with a poor nutritional status. Sixteen percent of stroke patients are already malnourished on admission to hospital. The incidence of dysphagia in patients with acute stroke ranges from 30 to 45%. Dysphagia increases the risk of developing poor nutritional status, and new cases of malnutrition develop during the hospital stay, even during the first week. In hospitals without routine nutritional assessment and individual nutrition management plans, the risk of patients developing malnutrition may be increased. In this study patients admitted for acute stroke are randomised into either receiving nutritional therapy derived from estimated individual nutritional intake and nutritional needs, or nutritional therapy based on routine care; without routine assessment of nutritional status, intake or needs. Nutritional therapy: enriched meals, sip-feedings or enteral feedings. Parameters of nutritional status: Weight, BMI, TSF thickness, mid upper arm circumference, body composition, s-albumin and s-transferrin. Estimation of nutritional intake: Daily registration of food and drink intake. Estimating functional status: Hand grip strength, Barthels ADL index and Scandinavian stroke scale. Estimating quality of life: EQ-5D.

Before the inclusion started we decided to use the percentage of patients with weight loss ≥ 5 % at 3 months follow-up as the primary outcome measure because this is correlated better to clinical outcomes as e.g. mortality and comorbidity. Secondary outcome measures were then defined as handgrip strength, quality of life, nutritional status, nutrient intake and length of hospital stay.
When progressive and severe, myasthenia gravis and Guillain-Barré syndrome may have the potential for fatal and unfavorable clinical outcomes. Regardless of important differences in their clinical course, the development of weakness of oropharyngeal muscles and respiratory failure with requirement of mechanical ventilation is the main driver of poor prognosis in both conditions. The need for prolonged mechanical ventilation is particularly relevant because it immobilizes the patient and care becomes extraordinarily complex due to daily risks of systemic complications. Additionally, patients with myasthenia gravis often require long-term immunosuppressive treatments with associated toxicity and infectious risks. Unlike myasthenia gravis, the recovery period is prolonged in Guillain-Barré syndrome, but often favorable, even in the more severely affected patients. Outcome, for a large part, is determined by expert neurocritical care.
Over 16 million adults in the United States are afflicted with chronic obstructive pulmonary disease (COPD) and is the fourth leading cause of death.(McCrory et al. 1190-209). COPD accounts for direct health-care costs of $18 billion.(McCrory et al. 1190-209). Oxygen therapy has been shown to decrease mortality in COPD patients with severe hypoxemia at rest. Oxygen therapy now accounts for the number one expenditure for durable medical equipment. Current requirements for oxygen therapy for COPD patients include a resting or exercise paO2 or spO2 of 55 mmHg or 88% respectively. We have shown that a resting spO2 of \< 95% is predictive of those at risk of exercise induced hypoxemia in COPD patients(Knower et al. 732-36) based on continuous spO2 monitoring during a 6 minute walk. Although, the reproducibility of a 6 minute walk has been addressed in terms of a hospital test, simulated home test and actual home test (Guyatt), its inter-variability is not well studied.

We propose to investigate the reliability and inter-variability of the 6 minute walk for oxygen prescription. Currently, two programs are providing pulmonary rehabilitation for COPD patients in the community. Patients perform 6 minute walks under supervision and are monitored by pulse oximetry on a routine basis as part of these programs. We plan to capture the oximetry data in order to determine the reliability of oxygen prescriptions using the 6 minute walk. Patients who are performing a 6 minute walk will be eligible for enrollment. Protocols for the 6 minute walk are already in place and approved by their respective authority in both of the Pulmonary Rehabilitation Programs. These patients will have repeat 6 minute walks on separate in close proximity to determine the reliability of spO2 on any given day. Statistical analysis will be done by the kappa statistic for inter-test agreement in a 3 dimensional matrix.

We ask to waive consent for this study as there is no change to the daily routine of the 6 minute walks already being done as part of Pulmonary Rehabilitation. We plan only to capture the data from these walks.
Nurse-led body protection education was provided to the intervention group in groups of 3-4 in 40 minutes. The education was provided as verbal narration by using a doll and distress whistle. In addition, two weeks after the post-test, a reminder education brochure prepared with the braille alphabet was distributed to the students in the intervention group.